Thu, Dec 18, 2014, 5:54 PM EST - U.S. Markets closed

Recent

% | $
Quotes you view appear here for quick access.

Star Scientific, Inc. (CIGX) Message Board

  • cigx1967 cigx1967 Jan 30, 2013 9:27 AM Flag

    Dr Curtis Wright

    The full report of the study is still being completed and will soon be submitted for peer review. Therefore, it is unavailable at this time. However, these promising initial results prompted Curtis Wright, MD, MPH, Medical Director of Rock Creek Pharmaceuticals, to comment, "It is remarkable that dietary supplementation is able to help lower the thyroid antibody activity. To see antibodies that may have been elevated for years beginning to come down in a significant way after three months of supplementation is exciting. Given the rate of decline over three months, it is quite reasonable to expect that the effect may continue with longer use, which has already been observed in individual cases. I look forward to following subjects over a longer period in order to establish how profound and clinically meaningful the effect is going to be. The thyroglobulin levels in some patients returned entirely to normal in this three month study."

    Sentiment: Strong Buy

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • Dr. Curtis Wright

      Dr. Wright brings a wealth of research and drug development and drug-abuse experience to Rock Creek Pharmaceuticals, where he serves as the company's Senior Vice President and Medical/Clinical director. Dr. Wright received his medical degree from the George Washington University and completed his initial training at Portsmouth Naval Hospital in the United States Navy. After nine years of naval service he completed his residency in Occupational and Preventive Medicine, and a Post-doctoral Fellowship, at the Johns Hopkins Medical Center in Baltimore, MD.

      Dr. Wright then worked as a medical review officer for the USPHS at the Food and Drug Administration in the areas of analgesics, anesthetics and drugs of abuse. During that tenure he was appointed Assistant Division Director and Acting Director for the Anesthetics, Analgesics and Life-Support Drugs Division.

      After leaving the FDA, Dr. Wright served in senior management and research positions for a number of biotech and major pharmaceutical firms, working in the development of novel and more abuse-resistant analgesic medications.

      Sentiment: Strong Buy

 
STSI
0.58010.0000(0.00%)Jun 3 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.